GNCA vs. SCPS, EVLO, GNCAQ, ARDS, STAB, AMPE, CMRA, EFTR, ONCSQ, and PXMD
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Genocea Biosciences vs.
Genocea Biosciences (NASDAQ:GNCA) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, analyst recommendations, media sentiment, community ranking, risk, institutional ownership and dividends.
Genocea Biosciences has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500.
Scopus BioPharma has lower revenue, but higher earnings than Genocea Biosciences.
Scopus BioPharma's return on equity of 0.00% beat Genocea Biosciences' return on equity.
0.6% of Genocea Biosciences shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Genocea Biosciences received 386 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 55.43% of users gave Genocea Biosciences an outperform vote.
In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.
Summary
Scopus BioPharma beats Genocea Biosciences on 5 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:GNCA) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy GNCA Stock Free GNCA Stock Alerts